Ludovica La Posta

Ludovica La Posta

Auto-generated profile, based on publicly available information

Ludovica La Posta

The University of Texas MD Anderson Cancer Center 12 Department of Genitourinary Medical Oncology Houston, Texas

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
YWYujia Wang
Yujia Wang
SCStefano Casarin
Stefano Casarin
MDMay Daher
May Daher
VMVakul Mohanty
Vakul Mohanty
MDMerve Dede
Merve Dede
Ken ChenKen Chen
Ken Chen
Adoptive cell therapies (ACT) leverage tumor-immune interactions to cure cancer. Despite promising phase I/II clinical trials of chimeric-antigen-receptor natural killer (CAR-NK) cell therapies, molecular mechanisms and cellular properties required to achieve clinical benefits in broad cancer spectra remain underexplored. While in vitro and in vivo experiments are essential, they are expensive, laborious, and limited to targeted investigations. Here, we present ABMACT (Agent-Based Model for Adoptive Cell Therapy), an in silico approach employing agent-based models (ABM) to simulate the continuous course and dynamics of an evolving tumor-immune ecosystem, consisting of heterogeneous “virtual cells” created based on knowledge and omics data observed in experiments and patients. Applying ABMACT in multiple therapeutic contexts indicates that to achieve optimal ACT efficacy, it is key to enhance immune cellular proliferation, cytotoxicity, and serial killing capacity. With ABMACT, in silico trials can be performed systematically to inform ACT product development and predict optimal treatment strategies.

1 October 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney neoplasm; bone metastasis (BM) develops in 35% to 40% of metastatic patients and results in substantial morbidity and mortality, as well as medical costs. A key feature of ccRCC is the loss of function of the von Hippel–Lindau protein, which enhances angiogenesis via vascular endothelial growth factor release. Consequently, antiangiogenic tyrosine kinase inhibitors (TKI) emerged as a treatment for ccRCC. However, limited data about their efficacy in BM is available, and no systematic comparisons have been performed. We developed mouse models of bone and lung ccRCC tumors and compared their anticancer efficacy, impact on mouse survival, and mechanisms of action, including effects on tumor cells and both immune and nonimmune (blood vessels and osteoclasts) bone stromal components. This approach elucidates the efficacy of TKIs in ccRCC bone tumors to support rational interrogation and development of therapies. Significance: TKIs showed different efficacy in synchronous bone and lung metastases and did not eradicate tumors as single agents but induced extensive reprogramming of the BM microenvironment. This resulted in a significant decrease in neoangiogenic blood vessels, bone remodeling, and immune cell infiltration (including CD8 T cells) with altered spatial distribution.

21 August 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
Niki Zacharias MillwardNiki Zacharias Millward
Niki Zacharias Millward
EREric S. Rupe
Eric S. Rupe
XCXinyue Chen
Xinyue Chen
RKRitesh Kotecha
Ritesh Kotecha
DRDamian Rieke
Damian Rieke
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultrarare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type (WT) epidermal growth factor receptor (EGFR) is a therapeutically actionable dependency in RMC and translated this insight into a deployable clinical regimen. Experimental Design: EGFR expression was assessed by Clinical Laboratory Improvement Amendments–certified immunohistochemistry in RMC tumors and by integrated RNA and chromatin immunoprecipitation sequencing of primary tumors and adjacent kidney. Panitumumab was compared with erlotinib in patient- and cell line–derived xenografts, and its mechanism defined by immunoblotting, confocal co-localization, cell-cycle and apoptosis assays, and natural killer (NK) cell coculture. Panitumumab-based therapy was then evaluated prospectively in 26 patients with RMC across 10 centers on two continents. Results: RMC showed uniformly high membranous EGFR (median H-score 300), with enhancer and promoter reprogramming at the EGFR locus and a ligand switch from EGF to epiregulin and amphiregulin. EGFR expression was uncoupled from SMARCB1 status in vitro. Panitumumab outperformed erlotinib in RMC xenografts, suppressed AKT and ERK1/2 signaling, and routed EGFR to LAMP1-positive lysosomes in vitro; its effect was predominantly cytostatic, with minimal NK cell–mediated cytotoxicity. Clinically, panitumumab-based therapy achieved a 53.9% objective response rate, including 15.4% complete responses, with median progression-free and overall survival rates of 5.8 and 9.5 months, respectively. Conclusions: WT EGFR is a foundational dependency in RMC that is effectively targeted by panitumumab-based therapy. These findings, derived from a nonrandomized registry, provide a biological and clinical rationale for further prospective validation.

3 April 2025
Verified
Other
Open access
PDF file
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
In vivo efficacy of TKIs in VHL- RENCA model over 20 days. A, B) Response to TKIs in bone (A) and lung (B) tumors detected by bioluminescence, mean + SEM, n = 8 to 16/group.

3 April 2025
Verified
Other
Open access
PDF file
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
Blood vessel marker expression in bone marrow and tumors. A, B) Detection of bone marrow (A) and tumor (B) blood vessels by confocal acquisition; blue, DAPI; yellow, endomucin; red, laminin; green, tumor GFP; white boxes, magnifications reported on right panels; arrowhead, lack of physical overlap between markers; C) Immunofluorescence detection of blood vessels in VHL- RENCA bone tumors by confocal microscopy; blue, DAPI; yellow, endomucin; red, laminin; green, tumor GFP; D) Quantification of blood vessel area inside and outside tumor area based on laminin (red) and endomucin (yellow) signal, mean + SEM, n=3-4/group; blue, DAPI; green, GFP; arrowhead, blood vessels with only one marker expressed. Bar, 10 µm. Endo-endomucin; Lam-laminin; IN T-inside tumor; OUT T-outside tumor.

8 October 2024
Verified
Other
Open access
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
Development of ccRCC models in bone. A, WT and KO sequence of the vhl gene of RENCA cells and Western blot analysis of VHL protein expression compared with the housekeeping protein, GAPDH. B, Schematic representation of the experimental models. Tumor cells were implanted into the tibia, and tissues were collected 7, 14, and 21 days after implantation. C and D, Tumor progression [UM-RC-3 (C) and RENCA VHL− (D) monitored in vivo by bioluminescence, mean ± SEM, n = 8–10 tibiae/group]. E and F, Confocal microscopy analysis of tumors in tibiae (RENCA VHL−, E; UM-RC-3, F). A quantification of tumor (green, GFP) and blood vessel (endomucin, yellow; laminin, red) areas over time is shown. Nuclei (blue, DAPI). Bar, 100 µm, mean ± SEM, n = 8–10 tibiae/group. G, Stereomicroscope images of lungs (brightfield and GFP); bar, 0.5 cm. H, Confocal microscopy analysis of tumors in lungs (RENCA VHL−); a quantification of tumor (green, GFP area) and blood vessel (CD31, red) areas over time is shown. Nuclei (blue, DAPI). Bar, 100 µm. Mean ± SEM, n = 8–10 tibiae/group. BV, blood vessel; Endo, endomucin; Lam, laminin; WT, wild-type.